PDCD1 and basal cell carcinoma: Anti-PD-1 antibodies like cemiplimab and pembrolizumab are now approved for treating advanced nonmelanoma skin cancers, due to their high mutational burden, including cutaneous squamous cell carcinoma and basal cell carcinoma.